Document detail
ID
doi:10.1007/s12094-023-03215-4...
Author
Ayala de la Peña, Francisco Antolín Novoa, Silvia Gavilá Gregori, Joaquín González Cortijo, Lucía Henao Carrasco, Fernando Martínez Martínez, María Teresa Morales Estévez, Cristina Stradella, Agostina Vidal Losada, María Jesús Ciruelos, EvaLangue
enEditor
Springer
Category
Medicine & Public Health
Year
2023
listing date
6/21/2023
Keywords
early breast cancer adjuvant neoadjuvant follow-up clinical breast cancerAbstract
Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing.
Thanks to the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages, despite the COVID-19 pandemic possibly having impacted these numbers (not yet quantified).
In recent years, locoregional and systemic therapies are increasingly being directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit.
New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody–drug conjugates have also improved outcomes in some patient subgroups.
This clinical practice guideline is based on a systematic review of relevant studies and on the consensus of experts from GEICAM, SOLTI, and SEOM.
Ayala de la Peña, Francisco,Antolín Novoa, Silvia,Gavilá Gregori, Joaquín,González Cortijo, Lucía,Henao Carrasco, Fernando,Martínez Martínez, María Teresa,Morales Estévez, Cristina,Stradella, Agostina,Vidal Losada, María Jesús,Ciruelos, Eva, 2023, SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022), Springer
MELAS: Phenotype Classification into Classic-versus-Atypical Presentations
presentations mitochondrial strokelike patients variability phenotype clinical melas
